Caption Management’s Theravance Biopharma TBPH Stock Holding History

Caption Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-248,700	Closed	-$4.04M	–	2035
2026 Q1	$4.04M	Buy	+248,700	New	+$4.4M	0.02%	591
2023 Q1	–	Sell	-50,000	Closed	-$561K	–	1535
2022 Q4	$561K	Sell	50,000 -10,000	-17%	-$105K	0.01%	897
2022 Q3	$608K	Buy	+60,000	New	+$562K	0.01%	1021
2022 Q2	–	Sell	-63,300	Closed	-$605K	–	1821
2022 Q1	$605K	Buy	+63,300	New	+$620K	0.01%	1105
2021 Q3	–	Sell	-15,000	Closed	-$217K	–	1799
2021 Q2	$217K	Sell	15,000 -15,000	-50%	-$282K	﹤0.01%	1169
2021 Q1	$611K	Buy	+30,000	New	+$570K	0.01%	771
2020 Q4	–	Sell	-30,000	Closed	-$443K	–	1236
2020 Q3	$443K	Buy	30,000 +9,000	+43%	+$169K	0.01%	796
2020 Q2	$441K	Buy	21,000 +8,500	+68%	+$218K	0.01%	694
2020 Q1	$289K	Buy	+12,500	New	+$313K	0.02%	648
2019 Q3	–	Sell	-100,000	Closed	-$1.63M	–	883
2019 Q2	$1.63M	Buy	100,000 +50,000	+100%	+$1.01M	0.08%	289
2019 Q1	$1.13M	Buy	+50,000	New	+$1.27M	0.06%	331

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

ICM

Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Caption Management's TBPH Position: Q2 2026 in Review

Caption Management sold out of Theravance Biopharma (TBPH) in Q2 2026, closing a stake of 163,704 shares — an estimated $2.66M sold.

Caption Management first reported a position in TBPH in Q1 2019 and held it in 8 quarters. The position peaked at $2.66M in Q1 2026. 180 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Caption Management reported no remaining Theravance Biopharma position as of Q2 2026 after selling out during the quarter.
Caption Management sold 163,704 Theravance Biopharma shares in Q2 2026, an estimated $2.66M.
Caption Management first reported a position in Theravance Biopharma in Q1 2019 and held it in 8 quarters.
Caption Management's Theravance Biopharma position peaked at $2.66M in Q1 2026.
180 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.